Source: Targeted Oncology, June 2025
The primary analysis of the phase 2 NEO-MEL-T study (NCT04139902) evaluating the neoadjuvant therapy of dostarlimab (Jemperli) plus the anti-TIM-3 agent cobolimab in high-risk resectable melanoma was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as a late-breaking abstract. In an interview with Targeted OncologyTM, Meghan Mooradian, medical oncologist at Massachusetts General Hospital, discussed findings and implications from the study.
Primarily, the treatment was well tolerated, with no unusual safety signals observed in either arm. The majority of toxicities reported were grade 1 or grade 2. Approximately 12% of patients experienced a grade 3 toxicity, but notably, there were no grade 4 or grade 5 events, and no events that prevented or delayed surgery.